NO331211B1 - ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿ - Google Patents

¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿

Info

Publication number
NO331211B1
NO331211B1 NO20075527A NO20075527A NO331211B1 NO 331211 B1 NO331211 B1 NO 331211B1 NO 20075527 A NO20075527 A NO 20075527A NO 20075527 A NO20075527 A NO 20075527A NO 331211 B1 NO331211 B1 NO 331211B1
Authority
NO
Norway
Prior art keywords
treatment
skin
connective tissue
tissue disorders
beta
Prior art date
Application number
NO20075527A
Other languages
English (en)
Other versions
NO20075527L (no
Inventor
Morten Sloth Weidner
Hans Christian Wulff
Original Assignee
Astion Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Pharma As filed Critical Astion Pharma As
Publication of NO20075527L publication Critical patent/NO20075527L/no
Publication of NO331211B1 publication Critical patent/NO331211B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer effektive og sikre medikamenter for behandlingen av bindevevssykdommer i huden, særlig med hensyn til behandlingen av kutane former av lupus erythematosus. Medikamentene omfatter som den terapeutisk aktive ingrediensen en ß2-adrenoreseptoragonist. Oppfinnelsen vedrører videre dermatologiske sammensetninger uten hudsensibiliseringsegenskaper og som inneholder enantiomert rene eller anrikede R-enantiomerer av ß2-adrenoreseptoragonisten.
NO20075527A 2005-04-13 2007-11-02 ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿ NO331211B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500529 2005-04-13
PCT/DK2006/050013 WO2006108424A2 (en) 2005-04-13 2006-04-12 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin

Publications (2)

Publication Number Publication Date
NO20075527L NO20075527L (no) 2008-01-14
NO331211B1 true NO331211B1 (no) 2011-10-31

Family

ID=36703472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075527A NO331211B1 (no) 2005-04-13 2007-11-02 ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿

Country Status (29)

Country Link
US (4) US8426475B2 (no)
EP (1) EP1719507B1 (no)
JP (1) JP5021621B2 (no)
KR (1) KR101355422B1 (no)
CN (1) CN101203214B (no)
AR (1) AR054249A1 (no)
AT (1) ATE473735T1 (no)
AU (1) AU2006233502B2 (no)
BR (1) BRPI0609361A2 (no)
CA (1) CA2604758C (no)
CY (1) CY1111541T1 (no)
DE (1) DE602006015387D1 (no)
DK (1) DK1719507T3 (no)
EA (1) EA016082B1 (no)
ES (1) ES2348920T3 (no)
HK (1) HK1091739A1 (no)
HR (1) HRP20100552T1 (no)
IL (1) IL186491A (no)
MX (1) MX2007012794A (no)
MY (1) MY147864A (no)
NO (1) NO331211B1 (no)
NZ (1) NZ562940A (no)
PL (1) PL1719507T3 (no)
PT (1) PT1719507E (no)
RS (1) RS51464B (no)
SI (1) SI1719507T1 (no)
TW (1) TWI366457B (no)
WO (1) WO2006108424A2 (no)
ZA (1) ZA200708748B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604826D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
US8268813B2 (en) 2006-07-10 2012-09-18 Intervet International B.V. Zilpaterol enantiomer compositions and methods of making and using such compositions
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
CN102267917B (zh) * 2011-06-15 2013-07-31 浙江工业大学 一种盐酸甲氧那明的合成方法
EP2849577A1 (en) * 2012-05-18 2015-03-25 Intervet International B.V. A method of enhancing performance in broiler chickens
GB2513297A (en) * 2013-03-08 2014-10-29 Univ Leicester Methods
CN104606177B (zh) * 2014-11-21 2018-02-02 苏州君宁新药开发中心有限公司 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用
WO2018000098A1 (en) * 2016-06-30 2018-01-04 Cipher Pharmaceuticals Inc. Treatment of inflammatory myopathies
CN106580978A (zh) * 2016-11-30 2017-04-26 郑州仁宏医药科技有限公司 一种治疗皮炎的西药组合物及其应用
JP7343500B2 (ja) * 2017-08-10 2023-09-12 アブロ ライフ サイエンシーズ，インコーポレーテッド 経皮薬物送達システム
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CA3161376A1 (en) 2019-12-18 2021-06-24 Anthony P. FORD Methods for improving neurological diseases and disorders
CN112300237A (zh) * 2020-04-13 2021-02-02 苏州恩泰新材料科技有限公司 海豹胆酸的制备方法及其应用
CA3196808A1 (en) * 2020-10-09 2022-04-14 Mc2 Therapeutics Ltd Treatment of dermatological conditions
CN116236467B (zh) * 2023-02-07 2023-10-27 中国人民解放军总医院 西马特罗或其衍生物的新用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097073A1 (en) * 2002-04-19 2003-11-27 Astion Development A/S Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7467B (en) 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferative skin diseases with b2 agonists
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
SU895445A1 (ru) * 1980-05-15 1982-01-07 Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова Способ лечени кожных форм красной волчанки
US4574129A (en) 1984-01-31 1986-03-04 Bristol-Myers Company Topical nonsteroidal anti-inflammatory methods
JPS61154201A (ja) 1984-12-26 1986-07-12 Matsushita Electric Ind Co Ltd 誘電体フイルタ
US4699777A (en) 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
PH25150A (en) 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US4980159A (en) 1989-05-23 1990-12-25 Bristol-Myers Squibb Company Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects
RU2092105C1 (ru) * 1989-11-20 1997-10-10 Нижегородский научно-исследовательский кожно-венерологический институт Способ определения терапевтической тактики у больных очаговой склеродермией и дискоидной красной волчанкой
DE4014252A1 (de) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
EP0540580B1 (en) 1990-07-26 1994-04-13 G.D. Searle & Co. Polymeric drug delivery system
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
JP3294876B2 (ja) 1992-07-20 2002-06-24 トキコ株式会社 給油装置
AU1533495A (en) 1994-01-12 1995-08-01 Byk Nederland Bv Phenyl ethanol amine ethers and uses thereof as beta-adreno-receptor agonists
JPH07304647A (ja) 1994-05-09 1995-11-21 Kao Corp マッサージ用組成物
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
GB9510162D0 (en) * 1995-05-19 1995-07-12 Bouras Elias Compositions for the treatment of skin conditions
JPH09110674A (ja) 1995-10-16 1997-04-28 Kao Corp 浴用剤組成物
FR2740040B1 (fr) 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
NZ500250A (en) * 1997-04-30 2001-03-30 Bridge Pharma Inc Adrenergic beta-2 agonist eutomers, feed compositions and use for increasing muscle and decreasing fat
US6254882B1 (en) * 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
JP2004507552A (ja) * 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
AU2002248910A1 (en) 2000-11-17 2002-05-27 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrmidines
KR100973665B1 (ko) 2001-12-03 2010-08-04 와이어쓰 엘엘씨 세포질 포스포리파제 ａ2의 억제제
WO2003088997A2 (en) * 2002-04-22 2003-10-30 Universiteit Utrecht Holding B.V. Reduction of unwanted immune reactions
AU2003228819A1 (en) * 2002-05-03 2003-11-17 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2509526A1 (en) * 2002-09-24 2004-04-15 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
US20040209850A1 (en) * 2003-04-15 2004-10-21 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
EP1646370A1 (en) 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
EP1689390B1 (en) * 2003-11-21 2011-02-09 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
CA2558126A1 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
WO2005102296A2 (en) 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
JP2008512433A (ja) * 2004-09-07 2008-04-24 ソセイ・アール・アンド・ディー・リミテッド 炎症性障害及び疼痛の治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097073A1 (en) * 2002-04-19 2003-11-27 Astion Development A/S Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
BRPI0609361A2 (pt) 2010-03-30
CY1111541T1 (el) 2015-08-05
EP1719507A1 (en) 2006-11-08
ZA200708748B (en) 2010-03-31
PT1719507E (pt) 2010-10-21
SI1719507T1 (sl) 2010-11-30
NZ562940A (en) 2010-02-26
MX2007012794A (es) 2008-02-22
AU2006233502B2 (en) 2011-07-28
KR101355422B1 (ko) 2014-02-06
DK1719507T3 (da) 2010-11-01
JP2008535873A (ja) 2008-09-04
US20130237607A1 (en) 2013-09-12
RS51464B (en) 2011-04-30
EA200702204A1 (ru) 2008-04-28
MY147864A (en) 2013-01-31
AU2006233502A1 (en) 2006-10-19
PL1719507T3 (pl) 2010-12-31
AR054249A1 (es) 2007-06-13
HK1091739A1 (en) 2007-01-26
US9907765B2 (en) 2018-03-06
CA2604758A1 (en) 2006-10-19
TWI366457B (en) 2012-06-21
CN101203214B (zh) 2012-11-21
EA016082B1 (ru) 2012-02-28
KR20080005957A (ko) 2008-01-15
WO2006108424A9 (en) 2007-08-09
ATE473735T1 (de) 2010-07-15
US20060235048A1 (en) 2006-10-19
ES2348920T3 (es) 2010-12-17
NO20075527L (no) 2008-01-14
JP5021621B2 (ja) 2012-09-12
IL186491A0 (en) 2008-08-07
US20190125699A1 (en) 2019-05-02
DE602006015387D1 (de) 2010-08-26
TW200719882A (en) 2007-06-01
IL186491A (en) 2011-12-29
WO2006108424A3 (en) 2006-12-14
HRP20100552T1 (hr) 2010-11-30
US20170157068A1 (en) 2017-06-08
WO2006108424A2 (en) 2006-10-19
US8426475B2 (en) 2013-04-23
EP1719507B1 (en) 2010-07-14
CN101203214A (zh) 2008-06-18
CA2604758C (en) 2014-11-25

Similar Documents

Publication Publication Date Title
NO331211B1 (no) ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20085158L (no) Farmasoytiske blandinger av ropinirol samt deres anvendelse
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
NZ603985A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
MX2009009623A (es) Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide.
BRPI0507895A (pt) composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório
EP2452686A3 (en) Methods and compositions for prevention and treatment of diabetic and aged skin
BR112014009851A2 (pt) moduladores de receptor de nmda e usos dos mesmos
EA200801243A1 (ru) Фармацевтическое применение замещенных амидов
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2012136969A3 (en) Ophthalmic treatments
NO20064584L (no) Tetrahydropyridoindolderivater
TW200611695A (en) Pyrrolopyridine derivatives
BRPI0615690B8 (pt) compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
NO20090205L (no) Cykliske derivater som modulatorer av kjemokin reseptor aktiviteten
WO2020068950A8 (en) Hdac1,2 inhibitors
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CIPHER PHARMACEUTICALS INC, CA

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTION PHARMA A/S, DK

CREP Change of representative

Representative=s name: VALUA APS, BORGMESTER JENSENS ALLE 25C, 1. SAL, 2100

MM1K Lapsed by not paying the annual fees